SCHEMBL19902317

SCHEMBL19902317

CCC(=O)c1cc(C(F)(F)F)nn1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
CYP3A4 P08684 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KDM4E B2RXH2 2/20 0.47
GRN P28799 1/20 0.47
SORT1 Q99523 1/20 0.47
POLB P06746 1/20 0.44
RAB9A P51151 2/20 0.43
TRPV1 Q8NER1 1/20 0.43
NPC1 O15118 1/20 0.43
CTSL P07711 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13545145 0.85 GRN (0.67) KDM4EGRNSORT1RAB9ACTSL
SCHEMBL3712192 0.81 ALDH1A1 (0.44) ALDH1A1CYP3A4HSD17B10KDM4EGRN
SCHEMBL13064210 0.81 KDM4E (0.51) ALDH1A1CYP3A4HSD17B10KDM4EGRN
SCHEMBL17920 0.81 GRN (0.71) ALDH1A1CYP3A4HSD17B10KDM4EGRN
SCHEMBL3711515 0.80 NPC1 (0.48) ALDH1A1CYP3A4HSD17B10KDM4EGRN
Hydrochloric Acid SCHEMBL8932269 0.79 GRN (0.69) ALDH1A1CYP3A4HSD17B10KDM4EGRN
SCHEMBL951323 0.79 KDM4E (0.50) ALDH1A1CYP3A4HSD17B10KDM4EGRN
SCHEMBL17732 0.79 KDM4E (0.50) ALDH1A1CYP3A4HSD17B10KDM4EGRN
SCHEMBL13020360 0.78 KDM4E (0.53) ALDH1A1CYP3A4HSD17B10KDM4EGRN
SCHEMBL30305711 0.78 KDM4E (0.49) ALDH1A1CYP3A4HSD17B10KDM4EGRN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10611776-B2 Spiroheptane salicylamides and related compounds as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2020-04-07 US disclosed
US-20190016735-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2019-01-17 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016735-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK ROCK1, MYLK, RHOA ALDH1A1 892/4885CYP3A4 3175/4885HSD17B10 1673/4885
US-10611776-B2 Spiroheptane salicylamides and related compounds as inhibitors of rock ROCK1, MYLK, RHOA ALDH1A1 892/4885CYP3A4 3175/4885HSD17B10 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.